CSL Behring Joins Santa Parade 2025 to Support Children Battling Illness

CSL Behring, a global biotechnology company headquartered in Minato, Tokyo, has announced its sponsorship and participation in the Santa Parade 2025. This charitable event aims to support children who are fighting illnesses such as pediatric cancer and rare diseases, as well as those in developing countries lacking adequate medical care due to poverty.

This year, employees and their families from CSL Behring will take part in two events: one in Tokyo on November 16 and another in Osaka on December 7. These parades are not just events; they represent a heartfelt effort to show solidarity and offer cheers to children facing health challenges.

Iizumi Yoshida, President and CEO of CSL Behring, expressed the company’s commitment to supporting those grappling with illness and their families. She stated, “Supporting individuals and families who confront illness is a crucial mission for us. The Santa Parade serves as a powerful reminder of the community's strength and the incredible courage it can inspire. This year, our employees and their families joined in to offer heartfelt encouragement.”

CSL Behring is dedicated to improving the quality of life for patients and their families through community partnerships. The company aims to enhance the lives of those it serves by focusing on rare diseases and creating a strong network of support rooted in scientific innovation and compassion.

The Santa Parade is not just about fundraising; it embodies the spirit of community connection. It brings together employees from various backgrounds who are committed to making a difference in the lives of children. The shared experience of participating in such an event fosters a sense of belonging and offers an opportunity for CSL Behring employees to engage with their community meaningfully.

For more information, the official Santa Parade websites are available:

- Tokyo: santarun.jp
- Osaka: santa-run.com

About CSL Behring

CSL Behring focuses on developing innovative biotherapeutics for the treatment and prevention of severe and rare diseases. The company has a mission to deliver these essential therapies to patients worldwide. In Japan, CSL Behring primarily operates in fields related to immunology, rare diseases, hereditary angioedema (HAE), hemophilia, and emergency care. Since its establishment, CSL Behring has made significant strides and celebrated its 20th anniversary in 2020. The company remains committed to enhancing the quality of care in Japan’s healthcare landscape. For more information, visit cslbehring.co.jp.

About CSL Limited

CSL Limited, traded on the ASX as CSL and on the US OTC as CSLLY, is a global biotechnology company with a diverse portfolio of life-saving medicines, including treatments for hemophilia, immunodeficiency syndrome, flu vaccines, and medications for iron deficiency and kidney disease. Since its founding in 1916, CSL has driven rich innovations by harnessing cutting-edge technologies. Today, more than 32,000 employees across three business areas—CSL Behring, CSL Seqirus, and CSL Vifor—work to save lives in over 100 countries. A blend of business strengths, research focus, and operational excellence fosters their unique capacity for developing innovative products that support enriched lives for patients.

For additional insights on the future of biotechnology, you can visit CSLBehring.com/Vita.

For inquiries, please contact CSL Behring Corporate Communications at +81-3-4213-0183.